Beyond the numbers: indirect ways to assess patient matching accuracy metrics
Part 4: Indirect and qualitative metrics for matching accuracy [Part 4] of Matching Accuracy...
Regulatory decision-making depends on evidence that reflects how medical products perform in real-world use, not only in controlled trials. For more than a decade, the Food and Drug Administration has relied on real-world data and real-world...
Part 4: Indirect and qualitative metrics for matching accuracy [Part 4] of Matching Accuracy...
As high-value therapies become the new norm,life sciences teams need closed claims data that...
HealthVerity COO Andrew Goldberg recently sat down with Quest Diagnostics’ Director, Health...
Open claims and closed payer claims data are essential for understanding the status and activities...
The FDA often requires some sort of post-market surveillance for medical devices to determine the...
Real-world data (RWD) offers a multitude of use cases that can benefit pharmaceutical companies...
Our series exploring the value of real-world data (RWD) throughout the pharmaceutical product life...
In our ongoing series, we have been discussing the value of real-world data (RWD) throughout the...
Two years ago, HealthVerity launched the Maternal Outcomes Masterset (MOM) to address the...
Historically, pharmaceutical manufacturers leveraged retail pharmacy prescriptions to identify...
Understanding PBC and today’s treatment landscape Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease marked by immune-mediated damage to the small bile ducts inside the liver. Over time, that injury can lead to cholestasis (reduc...